Sign In
Buy INZY
$4.00
+0 (+0%)
At Close: Sep 30, 2025
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
08:30am, Tuesday, 07'th May 2024
- Interim data from SEAPORT-1, a Phase 1 trial of INZ-701 in patients with end-stage kidney disease receiving hemodialysis, on track for fourth quarter of 2024 - - Interim data from ENERGY-1, a Phase
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:30am, Friday, 03'rd May 2024
BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for
- Favorable safety and immunogenicity profile in ABCC6 Deficiency, with clinical improvements in vascular pathology, visual function and patient reported outcomes (PROs) -
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:00pm, Friday, 05'th Apr 2024
BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics f
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference
08:30am, Tuesday, 02'nd Apr 2024
BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeuti
- Company to host conference call and webcast featuring key opinion leaders on Monday, April 8, 2024 at 8:00 a.m. ET - BOSTON, March 26, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (�
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights
08:30am, Tuesday, 12'th Mar 2024
– Topline data from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency expected in early April –
Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward
02:45pm, Friday, 08'th Mar 2024
Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward
Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference
08:30am, Monday, 26'th Feb 2024
- Douglas A. Treco, Ph.D., CEO and Chairman, to participate in panel discussion - - Douglas A. Treco, Ph.D., CEO and Chairman, to participate in panel discussion -
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:30am, Tuesday, 06'th Feb 2024
BOSTON, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics fo
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:30am, Tuesday, 05'th Dec 2023
BOSTON, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics fo
Inozyme: A Major Catalyst Is Uncomfortably Far Off
07:30am, Monday, 27'th Nov 2023
Inozyme is a rare disease therapy developer with a lead asset, INZ-701, targeting ENPP1 Deficiency and ABCC6 Deficiency. INZ-701 has shown safety and tolerability in trials and has the potential to im
Inozyme Pharma to Participate in Upcoming Investor Conferences
08:30am, Thursday, 09'th Nov 2023
BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutic
Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
08:30am, Tuesday, 07'th Nov 2023
– Patient recruitment underway in ENERGY-3 Pivotal Trial of INZ-701 in pediatric patients with ENPP1 Deficiency; topline data expected mid-2025 –
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Friday, 03'rd Nov 2023
BOSTON, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY)(“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for
